Who Is the MHRA and What Does It Do?

The Medicines and Healthcare products Regulatory Agency is a UK government agency, operating as an executive agency of the Department of Health and Social Care. Its mission is to protect and improve public health and patient safety by ensuring that medicines, medical devices, and blood components meet appropriate standards of safety, quality, and efficacy.

The MHRA authorises medicines for use in the UK, monitors the safety of licensed products after they reach the market, and takes enforcement action against products that pose risks or that are supplied without appropriate authorisation. It is the competent authority for medicines regulation in the UK.

The agency became fully independent of the European Medicines Agency (EMA) following the UK's departure from the European Union. Medicines previously authorised through the centralised EU procedure required new UK marketing authorisations. This transition is substantially complete as of 2026, though EMA guidance remains relevant as a reference standard for scientific and regulatory context.

The Primary Legislation: Medicines Act 1968

The Medicines Act 1968 is the foundational statute governing medicines in the United Kingdom. Enacted over fifty years ago, it has been substantially updated and supplemented by secondary legislation — most significantly the Human Medicines Regulations 2012 — but remains the primary legislative instrument.

The Act established the licensing framework for medicinal products, creating the principle that a product meeting the definition of a medicine requires authorisation before it can be placed on the market. Supplying an unlicensed medicinal product is an offence under the Act, subject to criminal penalties including fines and imprisonment.

A "medicinal product" under the Act is broadly defined: any substance or article manufactured, sold, supplied, imported, or exported that is administered to human beings for a medicinal purpose. A "medicinal purpose" includes treating, preventing, or diagnosing disease, or altering a physiological function.

The practical consequence is that the definition turns on intended use and presentation, not on molecular structure alone. A compound labelled "not for human use" may still meet the definition if it is, in practice, supplied for human administration.

The Human Medicines Regulations 2012

The Human Medicines Regulations 2012 (HMR 2012) are the primary secondary legislation implementing European medicines directives into UK law, and updating and consolidating the Medicines Act 1968 provisions. They set out the detailed requirements for marketing authorisation, manufacturing licences, wholesale dealer licences, and the rules governing advertising and labelling of medicinal products.

Under HMR 2012, supply of a medicinal product without a marketing authorisation is an offence. Importantly, the Regulations address the specific case of products presented as "for research use only." The MHRA's position — consistent with enforcement guidance — is that the RUO label does not automatically exempt a product from medicines law if the product is in practice intended for human use, if it makes implied medicinal claims, or if it is supplied in a form clearly designed for human administration (e.g., lyophilised powder in vials with human-use instructions).

Research Use Only (RUO) — What It Actually Means

The Research Use Only classification is a legitimate designation for compounds supplied to qualified researchers for genuine laboratory or preclinical research — work conducted in controlled settings, not involving human subjects in therapeutic or enhancement contexts. In this genuine context, RUO classification exempts a product from certain licensing requirements because the compound is not being supplied as a medicine.

The MHRA has noted that RUO designation has been widely misused in the grey market. Compounds labelled RUO but sold in quantities, formulations, and packaging clearly intended for individual human use — and marketed through channels targeting non-specialist consumers — do not fall within the legitimate RUO framework. The agency has taken enforcement action in cases where RUO labelling was used as a device to avoid medicines regulation while supplying what were effectively unlicensed medicines to consumers.

This does not mean all RUO-labelled peptides are illegal to possess in the UK. Personal importation for personal use occupies a different position in law from commercial supply. However, this is a nuanced area, and the distinction between personal import and supply is fact-specific. Any person seeking clarity on their specific situation should consult a solicitor with relevant expertise.

"The RUO label does not provide a blanket exemption from medicines regulation when the product is, in practice, intended for human use."

The Yellow Card Scheme

The MHRA operates the Yellow Card scheme, the UK's national pharmacovigilance system for reporting suspected adverse reactions to medicines, vaccines, and medical devices. Crucially, the scheme accepts reports relating to unlicensed products, including research peptides. This is significant for two reasons.

First, it demonstrates that the MHRA acknowledges the existence of adverse events associated with unlicensed peptides and actively collects data on them. Second, it provides a mechanism for anyone who experiences or witnesses an adverse event to contribute to the regulatory evidence base. Reporting suspected adverse reactions to the Yellow Card scheme (at yellowcard.mhra.gov.uk) is a responsible action and contributes to public health surveillance.

GLP-1 Agonists and the MHRA's 2024–2025 Enforcement Activity

In 2024 and 2025, the MHRA significantly increased its enforcement activity around unlicensed GLP-1 receptor agonist products — particularly unlicensed semaglutide and related compounds — in response to the surge in demand driven by licensed products such as Ozempic and Wegovy. The agency issued multiple public warnings, seized unlicensed stock, and commenced prosecution of suppliers.

This enforcement activity is relevant to the broader research peptide market for several reasons. It demonstrates that MHRA enforcement is not purely theoretical. It illustrates the agency's willingness to use existing legislation against grey-market supply. And it highlights the specific risk associated with compounds that are closely related to licensed medicines attracting very high levels of consumer demand — a category that includes several GLP-1 analogues commonly traded in the research peptide market.

What This Means in Practical Terms

The MHRA framework does not prohibit all engagement with research peptides. It prohibits, in particular, the supply of unlicensed medicinal products for human use. The practical implications vary by compound, by context, and by the specific activities involved. Rather than attempting to characterise any individual's specific legal position — which this educational guide is not equipped to do — the appropriate response to this regulatory landscape is straightforward:

The verification practices described elsewhere on this site — obtaining batch-specific COAs from independent laboratories, checking for credible HPLC and LC-MS data — are necessary but not sufficient. Compliance with the law, and appropriate medical oversight, are the prior conditions for any responsible engagement with this category of compounds.